The company’s oral, microbiome-changing therapy was well tolerated in patients with amyotrophic lateral sclerosis.

MaaT Pharma Announces Positive Phase 1b Results, Meeting Primary Endpoint in the Evaluation of MaaT033 in Amyotrophic Lateral ...

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival ...

MaaT Pharma’s quest to bring a microbiota-based therapy to market has moved a step forward with new data showing a benefit for its MaaT013 candidate in an early-access programme (EAP).

LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem ...

LYON, France--(BUSINESS WIRE)--Regulatory News: MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

This trend is a direct reflection of the continued demand from the medical community for MaaT Pharma’s drug candidate MaaT013. Nomination of Eric Soyer as Chief Financial Officer and transition ...

This trend is a direct reflection of the continued demand from the medical community for MaaT Pharma’s drug candidate MaaT013. Nomination of Eric Soyer as Chief Financial Officer and transition of ...